Contact
searchSearch
HMP Global
Login

News

News
Intratumoral Clostridium Novyi-Nontoxic Plus Pembrolizumab Demonstrates Clinical Promise Among Patients With Treatment-Refractory Advanced Solid Tumors
08/27/2025
Stephanie Holland
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a...
08/27/2025
Oncology
News
Pencil Beam Scanning Proton Therapy Demonstrates Long-Term Clinical Efficacy, Safety Among Children and Adolescents With Chordomas or Chondrosarcomas
08/07/2025
Stephanie Holland
Study results demonstrated that curative pencil beam scanning proton therapy demonstrated promising long-term efficacy and safety among children and adolescent/young adult patients with chordomas or chondrosarcomas.
Study results demonstrated that curative pencil beam scanning proton therapy demonstrated promising long-term efficacy and safety among children and adolescent/young adult patients with chordomas or chondrosarcomas.
Study results demonstrated that...
08/07/2025
Oncology
News
Palbociclib Monotherapy Demonstrates Modest Clinical Activity Among Patients With Locally Advanced or Metastatic Chordoma
08/04/2025
Stephanie Holland
According to final results from the NCT PMO-1601 trial, palbociclib monotherapy demonstrated modest clinical activity among patients with locally advanced or metastatic chordoma.
According to final results from the NCT PMO-1601 trial, palbociclib monotherapy demonstrated modest clinical activity among patients with locally advanced or metastatic chordoma.
According to final results from...
08/04/2025
Oncology
News
Sunitinib Plus Nivolumab for Patients With Advanced Extraskeletal Myxoid Chondrosarcoma
07/23/2025
Stephanie Holland
According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
According to results from the...
07/23/2025
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Promise in Advanced or Refractory Chordoma
07/22/2025
Stephanie Holland
According to results from an investigator-initiated phase 2 trial, camrelizumab plus apatinib demonstrated promising efficacy and safety among patients with advanced or refractory chordoma.
According to results from an investigator-initiated phase 2 trial, camrelizumab plus apatinib demonstrated promising efficacy and safety among patients with advanced or refractory chordoma.
According to results from an...
07/22/2025
Oncology
Conference Coverage
Concurrent Temozolomide Plus Radiotherapy Fails to Improve Survival for Patients With Non-Codeleted Anaplastic Glioma
07/08/2025
Stephanie Holland
According to results from the phase 3 CATNON trial, concurrent temozolomide plus radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients without 1p/19p codeletion anaplastic glioma.
According to results from the phase 3 CATNON trial, concurrent temozolomide plus radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients without 1p/19p codeletion anaplastic glioma.
According to results from the...
07/08/2025
Oncology
Conference Coverage
Concurrent Temozolomide Plus Radiotherapy Fails to Improve Survival for Patients With Non-Codeleted Anaplastic Glioma
07/08/2025
Stephanie Holland
According to results from the phase 3 CATNON trial, concurrent temozolomide plus radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients without 1p/19p codeletion anaplastic glioma.
According to results from the phase 3 CATNON trial, concurrent temozolomide plus radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients without 1p/19p codeletion anaplastic glioma.
According to results from the...
07/08/2025
Oncology
Conference Coverage
Dordaviprone Demonstrates Clinical Promise for Patients With Recurrent H3 K27M-Mutated Diffuse Glioma
07/01/2025
Stephanie Holland
According to results from a phase 1/2 study, dordaviprone demonstrated clinical promise and safety among adult and pediatric patients with recurrent H3 K27M-mutated diffuse glioma.
According to results from a phase 1/2 study, dordaviprone demonstrated clinical promise and safety among adult and pediatric patients with recurrent H3 K27M-mutated diffuse glioma.
According to results from a...
07/01/2025
Oncology
Conference Coverage
Dordaviprone Demonstrates Clinical Promise for Patients With Recurrent H3 K27M-Mutated Diffuse Glioma
07/01/2025
Stephanie Holland
According to results from a phase 1/2 study, dordaviprone demonstrated clinical promise and safety among adult and pediatric patients with recurrent H3 K27M-mutated diffuse glioma.
According to results from a phase 1/2 study, dordaviprone demonstrated clinical promise and safety among adult and pediatric patients with recurrent H3 K27M-mutated diffuse glioma.
According to results from a...
07/01/2025
Oncology
News
Outcomes for Patients With Central Nervous System Tumors Harboring NTRK Gene Fusions
02/11/2025
Allison Casey
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared...
02/11/2025
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use